massageblog
Member
But therapy is preferable to medication, one expert says
WebMD News from HealthDay
By Alan Mozes
HealthDay Reporter
WEDNESDAY, Jan. 14, 2015 (HealthDay News) -- A drug used to treat attention-deficit/hyperactivity disorder (ADHD) may also help treat binge-eating disorder, preliminary research suggests.
At higher doses tested, the prescription drug Vyvanse curtailed the excessive food consumption that characterizes binge-eating disorder, researchers said.
Vyvanse (lisdexamfetamine dimesylate) is solely approved in the United States to treat ADHD, and no drug has been approved to curb binge-eating disorder.
Binge-eating -- only recently recognized by the psychiatric community as a distinct disorder -- is characterized by recurrent episodes of excessive food consumption accompanied by a sense of loss of control and psychological distress, the study authors noted. It is also associated with obesity.
"Right now the most commonly used medications are epilepsy drugs," said study co-author Dr. James Mitchell, president of the Neuropsychiatric Research Institute in Fargo, N.D. "And they do help patients to eat well and cut down on weight," he added.
"However, their side effect profiles are not great, with their impact on cognitive [mental] impairment in particular making them difficult for many patients to tolerate," Mitchell said.
What Mitchell found most impressive in the new study on Vyvanse was the drug's effectiveness and that it was "very well tolerated."
The 14-week study, reported in the Jan. 14 online edition of JAMA Psychiatry, was funded by Shire Development, LLC, the manufacturer of Vyvanse.
The researchers tracked outcomes among roughly 260 patients with moderate to severe binge-eating disorder between 2011 and 2012.
All of the participants were between 18 and 55 years old, and none had a diagnosis of any additional psychiatric disorders, such as ADHD, anorexia or bulimia.
The volunteers were divided into four groups for 11 weeks. The first group received 30 milligrams (mg) of Vyvanse daily, while the second and third groups started with 30 mg a day, increasing to 50 mg or 70 mg (respectively) within three weeks. A fourth group took an inactive placebo pill.
Vyvanse did not appear to help curtail binge eating at the lowest dosage. But people taking the higher doses experienced a bigger drop in the number of days they binged each week compared with the placebo group, the researchers found.
WebMD News from HealthDay
By Alan Mozes
HealthDay Reporter
WEDNESDAY, Jan. 14, 2015 (HealthDay News) -- A drug used to treat attention-deficit/hyperactivity disorder (ADHD) may also help treat binge-eating disorder, preliminary research suggests.
At higher doses tested, the prescription drug Vyvanse curtailed the excessive food consumption that characterizes binge-eating disorder, researchers said.
Vyvanse (lisdexamfetamine dimesylate) is solely approved in the United States to treat ADHD, and no drug has been approved to curb binge-eating disorder.
Binge-eating -- only recently recognized by the psychiatric community as a distinct disorder -- is characterized by recurrent episodes of excessive food consumption accompanied by a sense of loss of control and psychological distress, the study authors noted. It is also associated with obesity.
"Right now the most commonly used medications are epilepsy drugs," said study co-author Dr. James Mitchell, president of the Neuropsychiatric Research Institute in Fargo, N.D. "And they do help patients to eat well and cut down on weight," he added.
"However, their side effect profiles are not great, with their impact on cognitive [mental] impairment in particular making them difficult for many patients to tolerate," Mitchell said.
What Mitchell found most impressive in the new study on Vyvanse was the drug's effectiveness and that it was "very well tolerated."
The 14-week study, reported in the Jan. 14 online edition of JAMA Psychiatry, was funded by Shire Development, LLC, the manufacturer of Vyvanse.
The researchers tracked outcomes among roughly 260 patients with moderate to severe binge-eating disorder between 2011 and 2012.
All of the participants were between 18 and 55 years old, and none had a diagnosis of any additional psychiatric disorders, such as ADHD, anorexia or bulimia.
The volunteers were divided into four groups for 11 weeks. The first group received 30 milligrams (mg) of Vyvanse daily, while the second and third groups started with 30 mg a day, increasing to 50 mg or 70 mg (respectively) within three weeks. A fourth group took an inactive placebo pill.
Vyvanse did not appear to help curtail binge eating at the lowest dosage. But people taking the higher doses experienced a bigger drop in the number of days they binged each week compared with the placebo group, the researchers found.